GeoVax Labs, Inc. (GOVX) NASDAQ

0.70

-0.0002(-0.03%)

Updated at September 08 04:00PM

Currency In USD

GeoVax Labs, Inc.

Address

1900 Lake Park Drive

Smyrna, GA 30080

United States of America

Phone

678 384 7220

Sector

Healthcare

Industry

Biotechnology

Employees

17

First IPO Date

September 25, 2020

Key Executives

NameTitlePayYear Born
Mr. David Alan DoddChairman, President & Chief Executive Officer570,3001950
Mr. Mark W. Reynolds CPAChief Financial Officer & Corporate Secretary348,2001962
Dr. Mark J. Newman Ph.D.Chief Scientific Officer422,6751955
Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Medical Officer501,1041951
Dr. Harriet Latham Robinson Ph.D.Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board01938
Mr. Thomas O'BrienVice President of Quality Systems & Compliance0N/A
Dr. John W. Sharkey Ph.D.Vice President of Business Development01956
Mr. Jeffrey WelchHead of Process Development & Manufacturing Operations0N/A

Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.